Immuno-SRM - Pioneering Proteomic Platform
Breakthrough Technology. Scientifically Proven.
IMMUNO-SRM IS GROUNDBREAKING
The Immuno-Selected Reaction Monitoring (SRM) platform is a novel proteomic screening solution that uniquely delivers rapid, scalable, and cost-effective detection of extremely low abundance peptide biomarkers in common dried blood spot specimens with high accuracy, effectiveness, and efficiency via familiar mass spectrometry workflows.
THE IMMUNO-SRM PLATFORM PROVIDES A CRITICAL SOLUTION
By quantifying low-abundance proteins, Immuno-SRM can help detect previously undetectable yet treatable genetic disorders. Key Proteo is developing a portfolio of expertly curated Immuno-SRM panels and a rapid, scalable, cost-effective workflow to enhance NBS programs in public health and other CLIA laboratory settings.
EASY TO IMPLEMENT WITH CURRENT LABORATORY WORKFLOWS
The Immuno-SRM platform provides a critical solution to identifying previously undetectable but treatable genetic disorders. Our proprietary technology integrates seamlessly with laboratory techniques and clinical workflows to advance current newborn screening programs and provide life-changing improvements to babies and families.
-
HIGH PERFORMANCE
Precision accuracy empowers healthcare professionals to make informed decisions without delay, optimizing resources and enhancing patient outcomes.
-
SCALABLE & EFFICIENT
Fast turnaround times, flexible batching, multiplex analysis, suitable with dried blood spot specimens, easily scalable with familiar mass spectrometry workflows.
-
COST-EFFECTIVE
Our technology is cost-effective with low capital expense requirements and low reagent costs per target.